Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have type 2 diabetes mellitus (T2DM) for at least 6 months
Have been treated with stable metformin dose for at least 3 months
Have HbA1c ≥7.5% and ≤11.0% at study entry
Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m\^2)
You may not be if
Have type 1 diabetes mellitus
Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not including prior short term insulin use (≤14 days)
Have been taking any other medicine for diabetes (other than metformin) during the last 3 months
Have used in the last 3 months (or plan to use) prescription weight loss medications
Have disorders associated with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
Current participation in or intent to begin during the study an organized diet and/or exercise weight reduction program (other than the lifestyle and dietary measures for diabetes)
Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial
Had chronic or acute pancreatitis any time prior to study entry
Have had a heart attack or stroke in the past 2 months, or have heart failure that significantly limits their physical activity
Estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73m\^2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory at study entry and confirmed at lead-in
Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Have proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator
Clareo Health | A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
